Novo Nordisk, a leading Danish drugmaker, a #freecashflow giant, and also the largest holding of #TTAI (FCF International Quality ETF), witnessed its shares skyrocket by a whopping 17.5% following significant revelations from the “SELECT” trial.
The data unveiled that their obesity drug, #Wegovy, has the potential to diminish the risk of major cardiovascular events, like heart attacks or strokes, by an impressive 20%.
These groundbreaking results not only exceeded analyst predictions but also present a pivotal moment for Novo Nordisk as it paves the way for #Wegovy to transition from its perception as merely a “vanity drug.” It’s not just about weight loss; it’s about potentially life-saving benefits!
Martin Holst Lange, Novo Nordisk’s executive VP for development, succinctly put it: the drug “has the potential to change how obesity is regarded and treated.” With a weekly injection of semaglutide 2.4 mg, the drug aims to significantly reduce the risk of cardiovascular incidents.
Stay informed and watch this space for more!
Source: CNBC
